Korea-based Samsung Medison has signed an agreement to acquire French startup and fetal ultrasound AI software developer Sonio.
Sonio will remain an independent company headquartered in France, according to Samsung Medison, and will continue its commercial growth independently while its products and services will remain compatible with all ultrasound device makers. The company's flagship product, Sonio Detect, received U.S. Food and Drug Administration (FDA) 510(k) clearance for analysis of prenatal ultrasound exams in August 2023.
Established in 2020, Sonio also announced in August 2023 that it had raised $14 million (€13 million) in series A funding to advance its ultrasound reporting software to accelerate research and development for image recognition and genomics, as well as to adapt the technology for portable ultrasound devices and point of care. The series A funding round was led by Cross Border Impact Ventures after an initial commitment from the European Innovation Council, according to a statement on the Sonio.ai website.
Samsung Medison's acquisition of Sonio is subject to regulatory approvals, including from the French Ministry of the Economy and Finance. Terms of the deal were not disclosed.
